Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Lixiana VTE Edoxaban Venous thromboembolism, treatment and recurrence prevention. Reimburse with clinical criteria and/or conditions Complete
Lodalis Colesevelam hydrochloride Hypercholesterolemia Do not list at the submitted price Complete
Lokelma sodium zirconium cyclosilicate Hyperkalemia, adults Do not reimburse Complete
Lonsurf trifluridine and tipiracil Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Lonsurf Trifluridine and Tipiracil mCRC Resubmission Do not reimburse Complete
Lonsurf Trifluridine and Tipiracil Metastatic Colorectal Cancer Do not reimburse Complete
Lonsurf Trifluridine-Tipiracil Gastric Cancer Reimburse with clinical criteria and/or conditions Complete
Lorbrena lorlatinib ALK-positive locally advanced or metastatic non-small cell lung Reimburse with clinical criteria and/or conditions Complete
Lorbrena Lorlatinib Non-Small Cell Lung Cancer (NSCLC) Do not reimburse Complete
Lotemax Loteprednol etabonate Post-operative inflammation following cataract surgery Do not list Complete
Lucentis Ranibizumab Macular edema, diabetic List with clinical criteria and/or conditions Complete
Lucentis Ranibizumab injection Macular edema, secondary to retinal vein occlusion List with clinical criteria and/or conditions Complete
Lucentis Ranibizumab Myopic choroidal neovascularisation List with criteria/condition Complete
Lucentis Ranibizumab Macular degeneration, age-related List with clinical criteria and/or conditions Complete
Lumakras sotorasib KRAS G12C-mutated advanced NSCLC Do not reimburse Complete
Lutathera lutetium oxodotreotide Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) Reimburse with clinical criteria and/or conditions Complete
Lutathera Lutetium Lu 177 dotatate Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Reimburse with clinical criteria and/or conditions Complete
Luxturna voretigene neparvovec Vision loss, inherited retinal dystrophy Reimburse with clinical criteria and/or conditions Complete
Lynparza olaparib gBRCAm, HER2-negative high-risk early breast cancer Reimburse with clinical criteria and/or conditions Complete
Lynparza olaparib Breast Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Lynparza Olaparib Newly Diagnosed OC Reimburse with clinical criteria and/or conditions Complete
Lynparza Olaparib metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Lynparza olaparib Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Lynparza Olaparib Ovarian Cancer Do not reimburse Complete
Lynparza (Resubmission) Olaparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete